Corporate News

FarmaMondo is pleased to announce the launch of its brand new website! After months of hard work and dedication, we are delighted to officially announce the launch on February 12, 2019. The new site launch is available and the URL is www.farmamondo.com The updated site includes changes to...

FarmaMondo Nordics Aps, a fully owned subsidiary of FarmaMondo SA, has received a GMP license from the Danish Medicines Agency. With this license in place, FarmaMondo Nordics provides a complete direct to hospital solution for Nordic region healthcare providers seeking the import and supply of unlicensed medicines through its...

FarmaMondo celebrates the recent successful establishment of its subsidiary in Copenhagen covering all 5 Nordic countries representing more than 27 million people. The Nordic expansion comes as a follow up to previous successful expansion to LATAM, Asia and CIS regions. FarmaMondo continues to invest...

Read the full interview, appeared on the magazine Healthcare and Life Sciences Review with our CEO, Mr. Jaron Spigel, regarding the uniqueness of FarmaMondo business model. With two billion people globally – predominantly in low and middle-income countries – having little or no access to medicine, a select group...

FarmaMondo is delighted to announce further expansion of its Russian operations. As of July 1st 2017 FarmaMondo Representative Office (Moscow, Russia) provides full service coverage to all Commonwealth Independent States (CIS) region. The enlarged Representative Office is a part of FarmaMondo’s global strategy of putting in place localized solutions...

Farmamondo and AOP Orphan signs an exclusive registration, marketing and distribution agreement for AOP’s novel therapy Tetrabenazine indicated for Huntington disease. The agreement covers the territory of Russian federation and is valid for 5 years with relevant milestones. Farmamondo’s local affiliate will be responsible to achieve Marketing Authorization and commercially...